SunTrust Banks Reiterates “$90.00” Price Target for Davita (NYSE:DVA)
SunTrust Banks set a $90.00 target price on Davita (NYSE:DVA) in a report published on Tuesday morning, The Fly reports. SunTrust Banks also issued estimates for Davita’s Q1 2020 earnings at $1.42 EPS, Q2 2020 earnings at $1.54 EPS, Q3 2020 earnings at $1.51 EPS, Q4 2020 earnings at $1.56 EPS, FY2020 earnings at $6.02 EPS and FY2021 earnings at $6.48 EPS.
Several other equities research analysts have also issued reports on the stock. Raymond James lowered shares of Davita from an outperform rating to a market perform rating in a research note on Thursday, November 7th. ValuEngine upgraded shares of Davita from a strong sell rating to a sell rating in a research note on Wednesday, January 15th. Wolfe Research lowered shares of Davita from an outperform rating to a market perform rating and set a $57.00 price objective on the stock. in a research note on Friday, October 25th. Sanford C. Bernstein began coverage on shares of Davita in a research note on Tuesday, November 12th. They set a market perform rating on the stock. Finally, Deutsche Bank began coverage on shares of Davita in a research note on Friday, January 3rd. They set a buy rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $71.43.
DVA stock traded down $0.26 during midday trading on Tuesday, hitting $85.98. The company’s stock had a trading volume of 863,642 shares, compared to its average volume of 1,174,992. The company has a debt-to-equity ratio of 4.26, a current ratio of 1.81 and a quick ratio of 1.77. Davita has a twelve month low of $43.40 and a twelve month high of $90.15. The company’s fifty day moving average price is $79.12 and its 200 day moving average price is $66.86. The stock has a market capitalization of $11.00 billion, a P/E ratio of 16.01, a PEG ratio of 0.63 and a beta of 1.70.
Institutional investors have recently added to or reduced their stakes in the company. Sciencast Management LP acquired a new position in shares of Davita during the 3rd quarter worth about $1,017,000. Bank of Hawaii bought a new stake in shares of Davita during the 3rd quarter worth about $430,000. Calamos Advisors LLC bought a new stake in shares of Davita during the 4th quarter worth about $450,000. Baxter Bros Inc. bought a new stake in shares of Davita during the 4th quarter worth about $1,672,000. Finally, First Hawaiian Bank bought a new stake in shares of Davita during the 4th quarter worth about $206,000. Institutional investors own 95.40% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: How does quantitative easing work?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.